Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yiqi Wenyang Sanhan Formula Combined With Acupoint Application in Allergic Rhinitis and Asthma Syndrome
NCT07540351Phase 1Not yet recruiting
- Sponsor
- Beijing Daxing District Hospital of Integrated Chinese and Western Medicine
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of Yiqi Wenyang Sanhan Formula and acupoint application patch in allergic rhinitis (AR) and asthma (2 arms), sponsored by Beijing Daxing District Hospital of Integrated Chinese and Western Medicine. Primary endpoints: Control of Allergic Rhinitis and Asthma Test at 4 weeks, Forced Vital Capacity at 4 weeks and 6 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
Yiqi Wenyang Sanhan Formulaacupoint application patch
03
Conditions
allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on NCT07540351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07540351.